Working… Menu

The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01881958
Recruitment Status : Withdrawn (the manufacturer decided to halt manufacturing the vaccine)
First Posted : June 20, 2013
Last Update Posted : March 6, 2018
Information provided by (Responsible Party):
Hadassah Medical Organization

Brief Summary:

Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.

The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.

Condition or disease Intervention/treatment Phase
Type One Diabetes Drug: DiaPep277® Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Estimated Study Start Date : January 2015
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: DiaPep277® Drug: DiaPep277®

Primary Outcome Measures :
  1. efficacy will be measured by comparing Hemoglobin A1c [ Time Frame: two years ]

Secondary Outcome Measures :
  1. Safety will be evaluated calculating number of Adverse Events. [ Time Frame: two years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Fasting C-peptide levels >= 0.2nmol/L.
  2. Diagnosis of type 1 diabetes
  3. No pregnancies or planned pregnancies of female subjects

Exclusion Criteria:

  1. The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the Investigator, are likely to affect the subject's response to treatment or the ability to complete the study.
  2. The subject has a history of any kind of malignant tumor (not including basal cell skin cancer).
  3. The subject has clinical evidence of any diabetes-related complication that in the opinion of the Investigator would interfere with the subject's participation in and/or completion of the study.
  4. Subject has history of endogenous allergic reactivity:

    • Severe allergic reaction or severe exacerbation of allergic asthma within 12 months prior to the Screening-Ext Visit.
    • Ongoing systemic asthma treatment.
    • Subjects with history of life threatening or severe allergy, re-occurrence of which cannot be ruled out based on the Investigator's judgment.
  5. The subject has known allergy to lipid emulsions.
  6. The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
  7. The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy or any medication that in the opinion of the Investigator might interfere with the study.
  8. The subject has any of the following clinically significant laboratory abnormalities:

    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of the normal (ULN) at the Screening-Ext Visit.
    • Total bilirubin greater than 1.3 times the ULN at the Screening-Ext Visit.
    • Subjects with severe renal failure at the Screening-Ext visit (as defined by glomerular filtration rate < 30 mL/min/1.73 m2 by Cockroft und Gault calculation • Clinically significant laboratory abnormalities, confirmed by repeat measurement, which may interfere with the assessment of safety and / or efficacy of the study drug, other than hyperglycemia and glycosuria at the Screening-Ext Visit.
    • Fasting triglycerides <1000 mg/dL (11.3 mmol/L) at the Screening-Ext Visit. Suitable medical therapy for treatment of hyperlipidemia is allowed.
  9. The subject is a known or suspected drug abuser.
  10. The subject is known to test positive for HIV antibodies.
  11. The subject has chronic hematologic disease.
  12. The subject has liver disease such as cirrhosis or chronic active hepatitis.

Layout table for additonal information
Responsible Party: Hadassah Medical Organization Identifier: NCT01881958     History of Changes
Other Study ID Numbers: 0224-13-HMO-CTIL
First Posted: June 20, 2013    Key Record Dates
Last Update Posted: March 6, 2018
Last Verified: March 2018